Pelizaeus–Merzbacher disease

From WikiMD's Wellnesspedia

(Redirected from Pelizaeus Merzbacher disease)


Prab-R-Tumpati-MD.jpeg

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss and sleep centers



WikiMD Resources for Pelizaeus–Merzbacher disease
Articles
Most recent articles on Pelizaeus–Merzbacher disease

Most cited articles on Pelizaeus–Merzbacher disease Review articles on Pelizaeus–Merzbacher disease

Articles on Pelizaeus–Merzbacher disease in N Eng J Med, Lancet, BMJ

Media
Powerpoint slides on Pelizaeus–Merzbacher disease

Images of Pelizaeus–Merzbacher disease Photos of Pelizaeus–Merzbacher disease

Podcasts & MP3s on Pelizaeus–Merzbacher disease Videos on Pelizaeus–Merzbacher disease

Evidence Based Medicine
Cochrane Collaboration on Pelizaeus–Merzbacher disease

Bandolier on Pelizaeus–Merzbacher disease TRIP on Pelizaeus–Merzbacher disease

Clinical Trials
Ongoing Trials on Pelizaeus–Merzbacher disease at Clinical Trials.gov

Trial results on Pelizaeus–Merzbacher disease Clinical Trials on Pelizaeus–Merzbacher disease at Google

Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Pelizaeus–Merzbacher disease

NICE Guidance on Pelizaeus–Merzbacher disease NHS PRODIGY Guidance

FDA on Pelizaeus–Merzbacher disease CDC on Pelizaeus–Merzbacher disease

Books
Books on Pelizaeus–Merzbacher disease
News
Pelizaeus–Merzbacher disease in the news

Be alerted to news on Pelizaeus–Merzbacher disease News trends on Pelizaeus–Merzbacher disease

Commentary
Blogs on Pelizaeus–Merzbacher disease
Definitions
Definitions of Pelizaeus–Merzbacher disease
Patient Resources / Community
Patient resources on Pelizaeus–Merzbacher disease

Discussion groups on Pelizaeus–Merzbacher disease Patient Handouts on Pelizaeus–Merzbacher disease

Directions to Hospitals Treating Pelizaeus–Merzbacher disease Risk calculators and risk factors for Pelizaeus–Merzbacher disease

Healthcare Provider Resources
Symptoms of Pelizaeus–Merzbacher disease

Causes & Risk Factors for Pelizaeus–Merzbacher disease Diagnostic studies for Pelizaeus–Merzbacher disease

Treatment of Pelizaeus–Merzbacher disease

Continuing Medical Education (CME)
CME Programs on Pelizaeus–Merzbacher disease
International / other languages

disease en Espanol disease en Francais

Business
Pelizaeus–Merzbacher disease in the Marketplace

Patents on Pelizaeus–Merzbacher disease

Experimental / Informatics
List of terms related to Pelizaeus–Merzbacher disease


Pelizaeus–Merzbacher disease is a rare central nervous system disorder in which coordination, motor abilities, and intellectual function are delayed to variable extents.[1]

Signs and symptoms[edit | edit source]

Hallmark signs and symptoms of Pelizaeus-Merzbacher disease include little or no movement in the arms or legs, respiratory difficulties, and characteristic horizontal movements of the eyes left to right.

The onset of Pelizaeus–Merzbacher disease is usually in early infancy. The most characteristic early signs are nystagmus (rapid, involuntary, rhythmic motion of the eyes) and hypotonia (low muscle tone). Motor abilities are delayed or never acquired, mostly depending upon the severity of the mutation. Most children with Pelizaeus–Merzbacher disease learn to understand language, and usually have some speech. Other signs may include tremor, lack of coordination, involuntary movements, weakness, unsteady gait, and over time, spasticity in legs and arms. Muscle contractures (shrinkage or shortening of a muscle) often occur over time. Mental functions may deteriorate. Some patients may have convulsions and skeletal deformation, such as scoliosis, resulting from abnormal muscular stress on bones.

Cause[edit | edit source]

Pelizaeus–Merzbacher disease is generally caused by a recessive mutation of the gene on the long arm of the X-chromosome (Xq21-22) that codes for a myelin protein called proteolipid protein 1 or PLP1. The disease occurs due to changes affecting the proteolipid protein 1 gene (PLP1) located on Xq22.2 leading to decreased myelination of nerve fibers.

The majority of disease-causing mutations result in duplications of the entire PLP1 gene. Deletions at the PLP1 locus (which are rarer) cause a milder form of Pelizaeus–Merzbacher disease than is observed with the typical duplication mutations, which demonstrates the critical importance of gene dosage at this locus for normal CNS function. Some of the remaining cases of Pelizaeus–Merzbacher disease are accounted for by mutations in the gap junction A12 (GJA12) gene, and are now called Pelizaeus-Merzbacher-like disease.

Other cases of apparent Pelizaeus–Merzbacher disease do not have mutations in either the PLP1 or GJA12 genes, and are presumed to be caused either by mutations in other genes, or by mutations not detected by sequencing the PLP1 gene exons and neighboring intronic regions of the gene. Among these is a genetic disorder (discovered in 2003,[2] 2004[3]) which is caused by mutation in the transporter of thyroid hormone, MCT8, also known as SLC16A2, is believed to be account for a significant fraction of the undiagnosed neurological disorders (usually resulting in hypotonic/floppy infants with delayed milestones). This genetic defect was known as Allan–Herndon–Dudley syndrome (since 1944) without knowing its actual cause. Some of the signs for this disorder are: Normal to slightly elevated thyroid-stimulating hormone, elevated T3 and reduced T4 (ratio of T3/T4 is about double its normal value). Normal looking at birth and for the first few years, hypotonic (floppy), in particular difficulty to hold the head, possibly difficulty to thrive, possibly with delayed myelination (if so, some cases are reported with an MRI pattern similar to Pelizaeus–Merzbacher disease,[4]) possibly with decreased mitochondrial enzyme activities, possibly with fluctuating lactate level. Patients have an alert face, a limited IQ, s may never talk/walk, 50% need a feeding tube, and have a normal lifespan. MCT8 can be ruled out with a simple TSH/T4/T3 thyroid test.

Diagnosis[edit | edit source]

The diagnosis of Pelizaeus–Merzbacher disease is often first suggested after identification by magnetic resonance imaging of abnormal white matter (high T2 signal intensity, i.e. T2 lengthening) throughout the brain, which is typically evident by about 1 year of age, but more subtle abnormalities should be evident during infancy. Unless a family history consistent with sex-linked inheritance exists, the condition is often misdiagnosed as cerebral palsy. Once a PLP1 or GJA12 mutation is identified, prenatal diagnosis or preimplantation genetic diagnostic testing is possible.

Classification[edit | edit source]

The disease is one in a group of genetic disorders collectively known as leukodystrophies that affect growth of the myelin sheath, the fatty covering—which acts as an insulator—on nerve fibers in the central nervous system. The several forms of Pelizaeus–Merzbacher disease include classic, connatal, transitional, and adult variants.

Milder mutations of the PLP1 gene that mainly cause leg weakness and spasticity, with little or no cerebral involvement, are classified as spastic paraplegia 2 (SPG2).

Treatment[edit | edit source]

No cure for Pelizaeus–Merzbacher disease has been developed, nor is there a standard course of treatment. Symptomatic and supportive treatment may include medication for seizures and spasticity. Regular evaluations by physical medicine and rehabilitation, orthopedic, developmental, and neurological specialists should be made to ensure optimal therapy and educational resources.[citation needed]

Prognosis is highly variable: patients with the most severe (connatal) form do not usually survive to adolescence, although with milder forms, survival into the sixth or seventh decades of life is possible. Genetic counseling should be provided to the family of a child with Pelizaeus–Merzbacher disease.[citation needed]

In December 2008, StemCells Inc. received clearance from the U.S. Food and Drug Administration to conduct phase I clinical trials of human neural stem cell transplantation at UCSF Children's Hospital.[citation needed] The company has since gone bankrupt.[citation needed]

In 2019 CRISPR and antisense therapy were successfully used to almost completely eliminate disease in a PMD animal model.

See also[edit | edit source]

References[edit | edit source]

Further reading[edit | edit source]

External links[edit | edit source]

Classification
External resources


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD